FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns treating a mammal with acute myeloid leukemia (AML), the disease of which depends on MCL-1. Method involves administering alvocidib, cytarabine and mitoxantrone to mammal cells with bone marrow cells having MCL-1 priming of at least 15 %, determined by exposing mammalian cells to mammalian mimetic BH3 selective for MCL-1, and determining the percentage change of mitochondrial polarization, which corresponds to priming MCL-1. Also disclosed is a method of treating a patient with AML comprising a preliminary determination of MCL-1 bone marrow priming.
EFFECT: group of inventions provides the effectiveness of treating patients with AML by preliminary prediction of the patient's response to alvocildib and the doctor's decision on prescribing alvocidib to the patient.
18 cl, 17 dwg, 8 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR | 2004 |
|
RU2367468C2 |
| METHOD FOR IDENTIFYING COMPOUNDS FOR TREATING CANCER | 2010 |
|
RU2575828C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| METHODS OF INFLUENCING TRANSCRIPTION CONTROL IN SUPER-ENHANCER AREAS | 2015 |
|
RU2737508C2 |
| METHODS OF TREATING, DIAGNOSING AND PREDICTING A HEMATOLOGIC MALIGNANT NEOPLASM | 2015 |
|
RU2727418C2 |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| NK INVOLVING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2812481C2 |
| COMPOSITIONS AND METHODS FOR MODULATING ACTIVITY OF AT2R | 2015 |
|
RU2721241C2 |
| CANCER TREATMENT WITH ROR1 ANTIBODIES IMMUNOCONJUGATES | 2020 |
|
RU2795560C2 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
